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Patient stratification based on biological variation in pancreatic ductal adeno-
carcinoma (PDAC) subtypes could help to improve clinical outcome. How-
ever, noninvasive assessment of the entire tumor microenvironment remains
challenging. In this study, we investigate the biological basis of dynamic con-
trast-enhanced (DCE), intravoxel incoherent motion (IVIM), and R2*-
derived magnetic resonance imaging (MRI) parameters for the noninvasive
characterization of the PDAC tumor microenvironment and evaluate their
prognostic potential in PDAC patients. Patients diagnosed with treatment-
na€ıve resectable PDAC underwent MRI. After resection, a whole-mount
tumor slice was analyzed for collagen fraction, vessel density, and hypoxia
and matched to the MRI parameter maps. MRI parameters were correlated
to immunohistochemistry-derived tissue characteristics and evaluated for
prognostic potential. Thirty patients were included of whom 21 underwent
resection with whole-mount histology available in 15 patients. DCE Ktrans
and ve, ADC, and IVIM D correlated with collagen fraction. DCE kep and
IVIM f correlated with vessel density and R2* with tissue hypoxia. Based on
MRI, two main PDAC phenotypes could be distinguished; a stroma-high
phenotype demonstrating high vessel density and high collagen fraction and a
stroma-low phenotype demonstrating low vessel density and low collagen
fraction. Patients with the stroma-high phenotype (high kep and high IVIM
D, n = 8) showed longer overall survival (not reached vs. 14 months,
P = 0.001, HR = 9.1, P = 0.004) and disease-free survival (not reached vs.
Abbreviations
ADC, apparent diffusion coefficient; CT, computed tomography; D*, pseudodiffusion coefficient; D, diffusion coefficient; DAB, 3,30-
diaminobenzidine; DCE, dynamic contrast-enhanced; DFS, disease-free survival; DWI, diffusion-weighted imaging; f, perfusion fraction;
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2 months, P < 0.001, HR 9.3, P = 0.003) compared to the other patients
(n = 22). Median follow-up was 41 (95% CI: 36–46) months. MRI was able
to accurately characterize tumor collagen fraction, vessel density, and hypoxia
in PDAC. Based on imaging parameters, a subgroup of patients with signifi-
cantly better prognosis could be identified. These first results indicate that
stratification-based MRI-derived biomarkers could help to tailor treatment
and improve clinical outcome and warrant further research.
1. Introduction
The severe desmoplastic reaction often present in pan-
creatic ductal adenocarcinoma (PDAC) has been asso-
ciated with dismal prognosis and therapy resistance
(€Ozdemir et al., 2014). This desmoplastic reaction
involves extensive fibrosis, severe immune infiltration,
and hypovascularization (Feig et al., 2012). As a result
of increased interstitial pressure and reduced vascular-
ization, pancreatic tumors often present with high
levels of hypoxia (Koong et al., 2000). Variation in
these three biological characteristics of PDAC –
desmoplasia, hypovascularization, and hypoxia – have
been related to differences in treatment outcome (Bai-
ley et al., 2016; Puleo et al., 2018).
Patient stratification based on this biological variation
could help to tailor treatment and improve clinical out-
come. However, characterization of the PDAC microen-
vironment in patients remains difficult, since (endoscopic)
biopsies often yield too little tissue for full characteriza-
tion and are prone to spatial sampling variation.
Quantitative magnetic resonance imaging (MRI),
such as dynamic contrast-enhanced (DCE), diffusion-
weighted imaging (DWI), and T2*-weighted MRI,
potentially enables noninvasive characterization of
desmoplasia, hypovascularization, and hypoxia of the
entire tumor (Gurney-Champion et al., 2018; Klaassen
et al., 2018a,b). In DCE MRI, imaging is performed
repeatedly after contrast injection and quantified by fit-
ting a multicompartment model to the tissue contrast
uptake curve. DWI uses gradients placed prior to the
signal readout to sensitize the MRI signal to the diffu-
sivity of water molecules. Cellular structures hamper
this water diffusivity, enabling DWI to characterize the
tissue using a mono-exponential function of the DWI
signal decay. The intravoxel incoherent motion (IVIM)
model (Le Bihan et al., 1988) uses a bi-exponential fit
to also model the faster perfusion-driven movement of
water molecules in the capillaries, enabling a separate
means of quantifying tissue perfusion. In R2* (the
reciprocal of T2*-relaxation time) MRI, the difference
in magnetic permeability between oxy- and
deoxyhemoglobin is exploited to determine tissue oxy-
genation. DCE (Bali et al., 2011; Ma et al., 2016) and
IVIM (Klauss et al., 2015; Lemke et al., 2009) have
demonstrated potential in characterizing PDAC lesions,
DWI has shown prognostic relevance in PDAC patients
(Heid et al., 2016), and studies in other cancer types
have shown the relation between hypoxia and R2*
(Hoskin et al., 2007). However, implementation of
imaging biomarkers in the clinical workup of PDAC is
not straightforward and still lacking. The exact interpre-
tation of the MR parameters is greatly dependent on
the underlying tissue conditions and used techniques.
Direct correlation to histology and patient outcome is
often lacking. In this study, we match surgery obtained
pathology to the MRI in an unprecedented way to
directly correlate the MRI parameters to histopathol-
ogy-derived tissue characteristics. Furthermore, we
investigated whether these parameters can be used as
noninvasive prognostic marker in patients with PDAC.
2. Materials and methods
2.1. Patients
For this prognostic study, patients were included at
the Amsterdam UMC, location AMC, during Novem-
ber 2013 and November 2017. Inclusion criteria com-
prised computed tomography (CT)-diagnosed high
suspicion of resectable PDAC (Dutch Pancreatic Can-
cer Group criteria, Versteijne et al., 2016), scheduled
for surgical exploration, a minimal eGFR of
30 mLmin11.73 m2, and no contraindications to
undergo MRI scanning. The study was approved by
the institutional review board of the Academic Medi-
cal Center (METC2013_254, NCT01989000) and per-
formed according to the standards set by the
Declaration of Helsinki. All patients gave written
informed consent before the start of the study. Patients
did not receive any oncological treatment before MRI
scans were performed. Complete clinical follow-up was
used until September 2018.
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2.2. Magnetic resonance imaging and processing
Magnetic resonance imaging was performed on a 3T
MR scanner (Ingenia, Philips, Best, the Netherlands)
on which we obtained quantitative DCE, T2*, and
DWI images. For anatomical verification, a multi-echo
spoiled gradient echo with three-point Dixon recon-
struction (mDIXON) sequence was performed 35 s
after contrast injection. Relevant sequence parameters
are summarized in Table 1.
Image processing was performed using in-house soft-
ware written in MATLAB (R2015b; MathWorks, Natick,
MA, USA), unless stated otherwise.
T2* and DCE data were obtained and processed as
described in detail in our earlier performed repeatabil-
ity study (Klaassen et al., 2018b). A mono-exponential
function was used to model the signal intensity decay
at different echo times to retrieve quantitative maps of
T2* and R2* relaxation rate. A population-based arte-
rial input function was used derived from another set
of pancreatic cancer patients using the same scan and
injection protocol (Klaassen et al., 2018b). The
extended Tofts model was fitted for each voxel to
retrieve parameter maps for the transfer constant
(Ktrans), rate constant (kep = K
trans/ve), extracellular
extravascular space (ve), and blood plasma volume
(vp). Voxels with unreliable fit results (ve > 1.0) were
discarded from further analysis.
Full details on DWI acquisition and data processing
are described in our previous work, where the acquisi-
tion was optimized (Gurney-Champion et al., 2016)
and used on a different set of PDAC patients (Gur-
ney-Champion et al., 2018; Klaassen et al., 2018a).
Diffusion coefficient (D), perfusion fraction (f), and
pseudodiffusion coefficient (D*) maps were obtained
by fitting the IVIM model to the signal decay as func-
tion of b-value using a least-squares fit. Additionally,
apparent diffusion coefficient (ADC) maps were
obtained using a mono-exponential fit to the signal
decay as function of all acquired b-values.
2.3. Histopathology processing and MRI
matching
Directly after resection, colored beads were sutured to
relevant anatomical structures (i.e., mesenteric vein
and artery margins, bile duct, and pancreatic duct)
and dissection planes of the resection specimen
(Fig. 1A left) and marked by a pathologist using col-
ored ink (Fig. 1A right). Independently, relevant
anatomical structures were annotated on the MRI and
reconstructed to form a 3D volume of the tumor area
(Fig. 1B). After overnight fixation in 4%
paraformaldehyde, the tissue was sliced in approxi-
mately 5-mm-thick axial-oriented slices that were num-
bered and photographed from both sides. One
complete tissue slice comprising evident tumor was
selected for whole-mount processing (Fig. 1C). Next,
the photographed slices were arranged and automati-
cally realigned to form a 3D volume of the pathology
specimen using the image scale obtained from an on
the photograph included ruler and an approximated
Table 1. Summary of the relevant MRI sequence parameters for DCE, T1 mapping, DWI, T2*, and mDIXON acquisition. FOV, field of view;
RL, right–left; AP, anterior–posterior; TR, repetition time; TE, echo time; TI, inversion time; FA, flip angle; Resp., respiratory.
DCE T1 DWI T2* mDIXON
Sequence type Fast Field Echo Look-Locker Echo Planar
Imaging
Multi-echo (8) Spoiled
Gradient Echo
Multi-echo (3) Spoiled
Gradient Echo
FOV (RL 9 AP, mm2) 400 9 400 400 9 350 432 9 108 400 9 355 400 9 350
Acquisition matrix 160 9 160 132 9 116 144 9 34 176 9 154 236 9 208
Slice thickness/gap (mm) 2.5 (5.0
noninterpolated)
5.7 (11.4
noninterpolated)
3.7/0.3 2.3 (4.6
noninterpolated)
1.7
Slices 30 13 18 41 53
TR/TE1/DTE (ms) 3.2/2.0/– 3.5/1.6/– > 2200/45/– 20/2.3/2.3 4.7/1.2/1.0
TI1/TI (ms) – 19/85 – – –
FA (°) 20 8 90 12 25
SENSE (RL/AP) 3.6/1.5 3/1.3 1.3 AP 1.5FH/2AP 2/1.5
Scan time (total) 1.75 s (280 s) 24 s ~ 10 min 22 s 21 s
Resp. compensation Postprocessing 1 breath hold Resp. trigger
(navigator)
1 breath hold 1 breath hold
DWI
b-values (smm2) and
(directions/averages)
0 (15), 10 (9),20 (9), 30 (9), 40 (9), 50 (9), 75 (4), 100 (12), 150 (4), 250 (4), 400 (4), 600 (16)
Diffusion times d/D (ms) 10.1/22.6
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slice thickness of 5 mm (IMAGEJ, STACKREG, Thevenaz
et al., 1998) (Fig. 1D). Next, the colored landmarks in
the 3D reconstructed pathology specimen were
matched to the manual annotations in the MRI in 3D
SLICER (https://www.slicer.org; Fedorov et al., 2012)
(Fig. 1E). This way, each slice in the pathology
specimen was matched to the MRI image slices assum-
ing approximately the same axial orientation for the
pathology and MRI slices as starting point. Further-
more, care was taken to find the best possible match
between MRI and pathology for the whole-mount pro-
cessed slice.
Axial Sagittal Coronal
A B
C D
E
F G VWF HIF1αPSRH&E
Histology quantification
H
I J
Pathology ROI projected on MRI Quantitative imaging (DCE ve)Quantitative pathology (PSR)
Fig. 1. Graphical representation of the pathology to MRI matching procedure. (A) Anatomical structures are marked in the tissue specimen.
(B) Anatomical structures are marked on the MRI. (C) The tissue specimen is sliced in axial-oriented slices. (D) The tissue specimen is
reconstructed in 3D MRI space by aligning the tissue slices. (E) The 3D reconstructed slices are projected onto the MRI and aligned to
match anatomical structures visible on both MRI and pathology. (F) The whole-mount slice is stained with H&E, and the tumor area is
annotated by a pathologist. (G) The tumor ROI is copied to the immunohistochemistry of the whole-mount slice. (H) The histology slices are
quantified. (I) The pathology ROI is projected onto the matched MRI. (J) The ROI is propagated to the quantitative histology and MRI.
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2.4. Immunohistochemical staining and
quantification
After fixation, tissue was dehydrated in a series of etha-
nol and embedded in paraffin. Four micrometer-thick
sections were cut on a Leica Polycut S Microtome
(Reichert Inc., Depew, NY), and tissue sections were
deparaffinized in xylene and rehydrated in a series of
ethanol. Whole-mount slides were histochemically
stained with hematoxylin (Klinipath; VWR Interna-
tional, Radnor, PA, USA) and eosin (H&E) and
stained for collagen with Picrosirius Red (PSR; Brun-
schwig, Basel, Switzerland). For immunohistochemical
(IHC) staining, sections were incubated in 0.3% hydro-
gen peroxide in methanol for 10 min. For endothelial
staining, heat-induced epitope retrieval (HIER) was
performed in 0.25% pepsin (Sigma, Saint Louis, MO,
USA) in 0.01 M hydrochloric acid for 15 min at 37 °C.
von Willebrand factor antibody (VWF, Agilent, Santa
Clara, CA, USA) was diluted in normal antibody dilu-
ent (Klinipath, 1 : 2000), and sections were incubated
at 4 °C overnight. For hypoxia staining, HIER was
performed in Tris/EDTA buffer solution at pH 9.0
(Lab Vision PT Module, Thermo Scientific, Waltham,
MA, USA) for 15 min at 98 °C. Hypoxia-inducible fac-
tor 1-alpha (HIF-1a) antibody (Clone 54, BD Bio-
sciences, Franklin Lakes, NJ, USA) was diluted in
normal antibody diluent (1 : 100), and sections were
incubated at 4 °C overnight. Subsequently, for all IHC
stainings BrightVision+ post-antibody block was
applied on the sections for 15 min at room temperature
followed by secondary antibody BrightVision Poly-
HRP-Anti Ms/Rb IgG (both Immunologic; VWR
International) for 30 min at room temperature. Stain-
ing was developed using Bright-DAB (Immunologic),
and sections were mounted in Pertex mounting medium
(Histolab, Askim, Sweden). PSR, VWF, and HIF-1a
slides were digitized with an Olympus dotSlide virtual
slide microscope (Olympus, Tokyo, Japan) using a 109
magnification.
Quantification of the digitized stained slices was
performed using a custom pipeline in MATLAB. PSR-
stained slides were converted into the (CIE)Lab color
space, with a 3-axis color system with dimension L
for lightness and a and b for the color dimensions,
and an absolute threshold was applied to the a-chan-
nel (green to red) to quantify the percentage of colla-
gen-positive tumor tissue. For all DAB-stained
images (VWF, HIF-1a), color deconvolution was per-
formed separating the brown DAB staining (Brey
et al., 2003). Next, this DAB channel was used to
automatically determine a threshold in the tumor
ROI using the maximum entropy approach to select
positively stained pixels. For the VWF-stained tissue,
the number of positively stained separate elements
after an 8-connected component (BWCONNCOMP, MAT-
LAB) operation with a minimum size of 50 pixels was
counted per mm2 to retrieve the vessel density. For
HIF-1a, the amount of positively stained nuclei, sepa-
rate elements after an 8-connected component (BW-
CONNCOMP, MATLAB) operation with a maximum size
of 200 pixels, in the tumor was expressed as a per-
centage of area.
2.5. ROI selections
Tumor ROIs were drawn on the whole-mount H&E-
stained slides under a microscope by a pathologist (JV)
specialized in HPB pathology with 15 years of experi-
ence (Fig. 1F) and copied to each separate digitized
(Fig. 1G) and quantified (Fig. 1H) staining. For further
analysis, average values from this ROI were used to
determine percentage of collagen per area (PSR), vessel
density per mm2 (VWF), and positively stained nuclei as
percentage of area (HIF-1a) for each tumor.
Based on the 3D matching of the pathology speci-
men to the MRI, the H&E-based ROIs were projected
onto the MRI and propagated onto the DCE and
DWI parametric maps for two axial slices (Fig. 1I).
Average values from these ROIs were calculated for
each quantitative parameter and correlated to the
quantified histology. In addition, IHC-stained and
quantified sections could be projected directly onto the
MR images along with the quantitative MR parameter
maps (Fig. 1J).
Since histopathology matching is not available in
clinical routine, separate ROIs were determined solely
based on the available imaging. Parametric maps of
DCE and DWI were projected on the anatomical
mDIXON image using 3D SLICER. ROIs were drawn in
evidently cancerous pancreas, showing lower perfusion
and/or infiltration on the mDIXON image, by a radi-
ologist (MRWE) with 9 years of experience in reading
abdominal MR images and a researcher (RK) with
4 years of experience in pancreatic MRI. When neces-
sary, contrast-enhanced CT scans were viewed next to
the MRI imaging for further reference. Care was taken
not to include biliary stents in the ROI when present.
2.6. Statistical analysis
Statistical analyses were performed in GRAPHPAD PRISM
(v5.01; GraphPad Software, La Jolla, CA, USA), R
(v3.4.4; R Core Team, 2018, R Foundation for Statis-
tical Computing, Vienna, Austria), and SPSS (version
24; IBM Corp., Armonk, NY, USA).
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Normality of the MRI and histology data was con-
firmed by the Kolmogorov–Smirnov test (P > 0.05).
Pearson’s correlation coefficients were calculated
between IHC and MRI parameters in the pathology
ROI and between MRI parameters for the clinical
ROI. Values were compared between patients with his-
tology-derived good-to-moderate (grades 1–2) and
poor tumor differentiation (grade 3) by Student’s t-
test. Overall survival (OS) was calculated from the
time of the MRI scan to the time of death after dis-
charge or until last follow-up. Disease-free survival
(DFS) was defined as the time between MRI and pro-
gressive disease determined at surgical exploration or
return of disease during follow-up. The maximum dif-
ference in log-rank test approach was used to deter-
mine prognostic value of the clinical ROI MRI
parameters for OS (Budczies et al., 2012). Kaplan–
Meier curves were drawn, and a log-rank test and Cox
proportional hazards model were used to determine
significance between groups. A multivariate Cox pro-
portional hazards model was applied for the MRI
parameters demonstrating a univariate relation for the
patients that underwent resection, adding T-stage at
resection (TNM7), resection margins (R-stage), patient
age, and gender.
3. Results
3.1. Patients
From the 37 patients initially included in the study, data
of 30 patients could be used for analyses. Two patients
did not undergo MRI scanning due to early progression
and a late detected contraindication for MRI scanning.
Five patients were excluded after MRI scanning, due to
different underlying etiologies of the pancreatic lesions
determined at histopathological examination of the
resection specimen (1 cholangiocarcinoma, 1 nonmalig-
nant intraductal papillary mucinous neoplasm, 1 pan-
creatitis, and 2 neuro-endocrine tumors). Of these 30
patients, 21 underwent a resection and whole-mount
histology was available in 15 patients (Fig. 2). Patient
demographics are summarized in Table 2.
3.2. Quantitative MRI correlates with histology
For the 15 patients from whom whole-mount histol-
ogy was available, the whole-mount H&E-based
Failed to complete MRI
n = 2
Initial inclusion
n = 37
No resection n = 9
No WM available n = 6
Pre-OR MRI
n = 35
Other pathology
 n = 5 
Data analyzed
n = 30
WM correlation
n = 15
Fig. 2. Patient inclusion. Initially, 37 patients were included in the
study. Two patients did not undergo MRI scanning, and five
patients were excluded after MRI scanning. The resulting data of
30 patients were used for further analyses, of which 21 underwent
resection and whole-mount (WM) histology was available in 15
patients.
Table 2. Basic patient characteristics for all patients included in the
analyses. M1, metastasized disease; LA, locally advanced disease;
FU, follow-up; CI, confidence interval.
Variable Value (range)
Number of patients 30
Mean age (years) 63 (47–81)
Gender
Male 18
Female 12
Tumor location
Head 25
Corpus 2
Tail 3
Tumor diameter PA (mm) 33 (15–55)
Resection
No 9 [8 M1, 1 LA]
R0 10
R1 11
Differentiation grade
Well 2
Moderate 8
Poor 9
No resection 9
Missing 2
Time between MRI and Surgery (days) 9 (1–32)
Median FU (months, 95% CI) 41 (36–46)
Median OS (months, 95% CI) 18 (14–22)
Median DFS (months, 95% CI) 8 (1–14)
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tumor ROIs were propagated to the MRI. Resulting
median MRI ROI volumes were 2.9 cm3 (range 1.5–
4.9 cm3) for DWI (n = 15) and 1.9 cm3 (range 1.2–
4.9 cm3) for DCE and R2* (n = 15). Since the ROI
was propagated to two MRI slices and the slice
thickness was different between the MRI sequences
for DCE/T2* and DWI, the resulting ROI volumes
were different. For DCE analysis, a median of 89%
(range 57–100%) of the voxels showed a reliable fit
result (ve < 1.0) in the pathology ROI. IVIM fits
resulted in a median R2 in the pathology ROI of
0.73 (range 0.34–0.89).
We then set out to assess whether the three rele-
vant biological characteristics of PDAC – collagen
fraction, vessel density, and hypoxia – could be
assessed with functional MR. Mean parameter values
for DCE, R2*, and DWI and relevant correlation
coefficients with parameters derived from histology
are summarized in Table 3. An example of a patient
MRI showing the quantitative parameter maps with
corresponding histopathology is shown in Fig. 3A,B.
We observed a significant correlation between PSR,
as a measure of collagen fraction, and DCE Ktrans
and ve (Fig. 3C,D) as well as IVIM D and ADC
(Fig. 3G,H). VWF, quantifying vessel density, corre-
lated significantly with DCE kep (Fig. 3E) and IVIM
f (Fig. 3I). The amount of HIF-1a positively stained
nuclei, as a measure of hypoxia, demonstrated a sig-
nificant association with R2* (Fig. 3F). There was a
significant difference in IVIM D between tumor dif-
ferentiation grades (Fig. 3J).
4. Quantitative MRI parameters show
prognostic potential
For survival analysis, the clinical MRI ROIs from all
30 included patients were used. These ROIs resulted in
median surface area of 3.2 cm2 (range: 1.8–6.6 cm2).
For DCE analysis, a median of 85% (range 21–100%)
of the voxels showed a reliable fit result (ve < 1.0) in
the clinical MRI ROI. IVIM fits resulted in a median
R2 in the clinical MRI ROI of 0.75 (range 0.47–0.92).
Correlations between the different MRI parameters
are summarized in Table 4. DCE kep and IVIM f
(r = 0.54, P = 0.002) demonstrated a positive correla-
tion, and both correlated to vessel density in the com-
parison to histology.
Based on the maximum difference in log-rank test
approach, we were able to identify prognostic cutoff
values for kep and IVIM D. Patients with
kep > 0.397 min
1 (n = 15) demonstrated longer OS
and DFS compared to patients with lower kep
(Fig. 4B,C). The cutoff for IVIM D
(1.375 9 103 mm2s1) divided the group into 16
patients with high and 14 with low IVIM D, demon-
strating longer OS and DFS for the patient with
higher tumor diffusivity (Fig. 4D,E).
Combining the findings from the histological corre-
lation and survival analysis, two main phenotypes
could be distinguished, a stroma-high phenotype
demonstrating high vessel density and high collagen
fraction and a stroma-low phenotype demonstrating
low vessel density and low collagen fraction. In
Table 3. Mean values and correlations between MRI and histology-derived parameters in the pathology ROI. r, Pearson’s correlation
coefficient; vp, blood plasma volume.
Parameter Mean  SD
PSR
Collagen fraction (%)
VWF
Vessel density
(mm2)
HIF-1a
Hypoxia (mm2)
42.81  12.50 83.86  14.21 933.5  249.3
r P r P r P
Ktrans (min1) 0.20  0.07 0.76 < 0.001 0.10 0.717 0.38 0.184
kep (min
1) 0.45  0.12 0.10 0.722 0.61 0.017 0.09 0.768
ve (–) 0.46  0.13 0.73 0.002 0.44 0.098 0.28 0.329
vp (–) 0.03  0.02 0.53 0.042 0.17 0.551 0.26 0.360
R2* (Hz) 28.56  14.31 0.19 0.510 0.05 0.850 0.56 0.039
ADC (103 mm2s1) 1.48  0.25 0.62 0.014 0.16 0.568 0.33 0.254
IVIM D (103 mm2s1) 1.32  0.25 0.75 0.001 0.15 0.598 0.35 0.223
IVIM f (%) 5.49  3.57 0.23 0.416 0.65 0.009 0.01 0.979
IVIM D* (103 mm2s1) 94.02  55.51 0.21 0.456 0.20 0.486 0.17 0.551
Bold values indicates P < 0.05
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Fig. 4A, the typical difference in tumor biology
between these two phenotypes is illustrated. Patients
with the stroma-high phenotype (high kep and high
IVIM D, n = 8) showed longer OS compared to the
other patients (Fig. 4F,G).
At the time of surgical exploration, nine patients
turned out to have metastatic or irresectable disease.
No significant differences in imaging parameter
between patients with resectable and unresectable
tumors were found. However, since the latter were
subsequently treated with palliative rather than cura-
tive intent, we repeated the survival analysis for
patients who underwent a resection of the primary
tumor. In this group, kep was still prognostic for OS
and DFS (Fig. 5A,B). Multivariate Cox regression
demonstrated that kep was an independent predictor
for OS (HR = 5.8, P = 0.012, n = 19) and DFS
(HR = 8.0, P = 0.022, n = 19) in addition to standard
clinical parameters. IVIM D was not prognostic for
OS or DFS in this subset of patients (Fig. 5C,D). The
stroma-high phenotype still showed longer OS and
DFS (Fig. 5E,F). Multivariate analysis on the subtypes
also showed the added value of the imaging parame-
ters for predicting OS (HR: 19.5, P = 0.039) and DFS
(HR: 23.5, P = 0.02).
5. Discussion
In this preliminary study, we found that quantitative
MRI parameters correlate with tumor collagen frac-
tion, vessel density, and hypoxia, which are considered
important hallmarks in determining the poor outcome
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of PDAC. Using quantitative MRI, we identified two
PDAC phenotypes, stroma-high and stroma-low,
which were associated with significant differences in
prognosis.
Multiple clinical (Bali et al., 2011; Ma et al., 2016;
Xu et al., 2017) and preclinical (Wegner et al., 2016,
2017; Wu et al., 2015) studies have investigated the
relations between DCE-derived quantitative parame-
ters and histological tissue properties in PDAC. How-
ever, none of these studies performed an extensive
pathology matching procedure as done in this study.
We found a positive correlation between Ktrans, ve, and
collagen fraction. Although we did not find a correla-
tion between vascular density and Ktrans as was found
in a preclinical setting (Wegner et al., 2017), we did
find that Ktrans is associated with the amount of colla-
gen deposition in the tumor. In addition, when Ktrans
was divided by the extracellular compartment (ve),
which we and others have associated with collagen
deposition in a (pre)clinical setting (Bali et al., 2011;
Ma et al., 2016; Wegner et al., 2016; Xu et al., 2017),
we found that the resulting kep was able to detect the
relatively small differences in vascularity between
PDAC tumors. This might suggest that vascular flow
and permeability in PDAC are more dependent on the
tumor micro-environmental properties associated with
a collagen-rich microenvironment than the actual
amount of vessels that are present.
In some parts of the tumor with very low perfusion,
information is hard to extract using a perfusion-based
method as DCE, due to the lack of contrast enhance-
ment in these regions. This is not an issue for IVIM f,
an IVIM-based measure for perfusion fraction, which
also demonstrated a correlation with tumor vascularity
from histology. Thus far, only one other study found
a positive correlation between IVIM f and vessel den-
sity in PDAC (Klauss et al., 2015). However, this
study also included highly perfused neuro-endocrine
tumors. Although in our study IVIM f did show a cor-
relation with both tumor vascularity and kep, it did
not associate with survival. The limited reproducibility
of IVIM f, as we demonstrated previously (Gurney-
Champion et al., 2018), and the more limited image
quality of the quantitative maps to determine an
image-based ROI could explain this result.
Studies investigating the correlation between DWI,
collagen deposition, and cellular density in PDAC
have reported contradictory results. Some studies have
demonstrated a positive correlation between collagen
deposition and ADC (Heid et al., 2016; Klauss et al.,
2013), where others demonstrated lower diffusivity in
dense fibrosis (Hecht et al., 2017; Ma et al., 2016;
Muraoka et al., 2008; Xu et al., 2017) or noT
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Based on the maximum difference in log-rank test approach, kep was prognostic for OS (X vs. 13 months, P = 0.002, HR: 3.7, P = 0.005,
n = 30) and DFS (13 vs. 3 months, P < 0.001, HR: 3.8, P = 0.004, n = 30), with X being the median survival not yet reached. (D, E) IVIM D
was prognostic for OS (19 vs. 16 months, P = 0.033, HR: 2.5, P = 0.043, n = 30) and DFS (13 vs. 0 months, P = 0.006, HR: 3.0, P = 0.016,
n = 30). (F, G) The combination of kep and IVIM D into tumor phenotypes (stroma-low, stroma-high) improved the prognostic value for both
OS (X vs. 14 months, P = 0.002, HR: 9.1, P = 0.004, n = 30) and DFS (X vs 2 months, P < 0.001, HR: 9.3, P = 0.003, n = 30). With P-
values for survival differences being derived from log-rank tests and for HR from Cox regression.
2185Molecular Oncology 14 (2020) 2176–2189 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
R. Klaassen et al. Characterization of pancreatic cancer with MRI
correlation between ADC and stromal content (Xie
et al., 2015). However, none of these studies included
a histological comparison as large and detailed as our
whole-mount approach. Heid et al. (2016) demon-
strated recently that ADC correlates inversely with cel-
lular density. This would support our current findings
since, for PDAC tumors with high cellular density, col-
lagen fraction is lower and vice versa.
Our survival analysis demonstrated that higher
tumor diffusivity is a good prognostic factor. This is
in line with earlier studies investigating the prognostic
value of ADC in PDAC (Heid et al., 2016; Kurosawa
et al., 2015). DCE-derived kep performed even better
as prognostic marker in our study. Although tumor
vascularity is a known prognostic factor in PDAC
(Hoem et al., 2013), so far only one imaging-based
study demonstrated a difference in survival, based on
static contrast enhancement on CT (Fukukura et al.,
2014). Patients demonstrating a stroma-high pheno-
type had better outcome. From a biology perspective,
these tumors are characterized by dense collagen con-
tent and good vascularization and are relatively well
differentiated. This suggests that collagen and tumor
stroma can have a protective, or tumor-constraining,
role in PDAC. This is supported by a recent clinical
study, indicating that the presence of stroma restrains
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Fig. 5. Survival analyses for the patient that underwent resection of the primary tumor. (A, B) kep was prognostic for OS (X vs. 14 months,
P = 0.002, HR: 4.7, P = 0.007, n = 21) and DFS (X vs. 8 months, P < 0.001, HR: 5.7, P = 0.003, n = 21). (C, D) IVIM D was not prognostic
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the progression of basal-like tumors and improves sur-
vival in patients with stroma-activated and desmoplas-
tic tumor subtypes, whereas for well-differentiated
tumors, survival is reduced when a stromal signal is
present (Puleo et al., 2018). In addition, preclinical
studies in genetically engineered mouse models
revealed that depletion of the tumor stroma as a treat-
ment strategy for PDAC resulted in more aggressive,
dedifferentiated tumors and reduced survival (€Ozdemir
et al., 2014; Rhim et al., 2014). In addition, phase I
and II trials using IPI-926 – a Hedgehog inhibitor
depleting the tumor-associated stroma – were stopped
early due to detrimental effects: PDAC patients receiv-
ing this regimen showed shorter survival (Catenacci
et al., 2013). However, whether the differentiation
grade of tumor cells defines the stromal content or the
stromal cells define the differentiation grade of tumor
cells remains to be elucidated. Especially, stroma-low
tumors, where vessel density is low, would also be
prone to develop hypoxia, another known prognostic
factor in PDAC (Kitada et al., 2003). We could not
find a direct correlation between vascularization, diffu-
sivity, and HIF-1a positivity in our study. R2* on the
other hand did show an association with tumor hypox-
ia, which implies that PDAC hypoxia is driven by a
complex combination of factors and could benefit
from more targeted imaging strategies (Klaassen et al.,
2015).
Some limitations of our study should be taken into
account. First, for both histological correlations and
survival analysis the number of patients investigated is
limited. However, our approach of directly matching
the histology to the MR does add to the validity of
the found correlations between histology and quantita-
tive imaging. Furthermore, the prognostic value found
for DWI is in line with previous findings. Second, the
larger voxel size of MRI compared to histology makes
comparison of intratumoral regions more difficult, and
in our current approach, only one 4-µm slice was
available from histology. We therefore correlated aver-
age values derived from only one tumor slice, thereby
neglecting intratumor heterogeneity in the current
analyses. The addition of a MRI-based 3D mold to
enable more accurate slicing and orientation of the
pathology specimen relative to the MRI (Costa et al.,
2017) might help to improve the match between MRI
and histology and facilitate heterogeneity analysis.
Third, the generalizability of our findings could be lim-
ited by the variation in acquisition and postprocessing
methods available and standardization of these imag-
ing methods is necessary when implementing these
techniques on a larger scale (O’Connor et al., 2017;
QIBA, 2012, 2019; Taouli et al., 2016).
6. Conclusions
In conclusion, quantitative MRI methods are able to
quantify tumor collagen fraction, vessel density, and
hypoxia in PDAC. Based on the imaging-derived char-
acteristics, we identified that patients with a stroma-
high phenotypes, described by a high collagen fraction
and high vessel density, and demonstrated significantly
better outcome compared to other patients. These find-
ings may help to improve stratification of patients for
treatment and warrant further research on this topic.
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